journal article·2023-12Open access

Engineering a metastatic stroma directs the osteosarcoma tumour transcriptome in a spatially specific manner

Deniz Bakkalci, Georgina Al-Badri, Wei Yang, Andy Nam, Yan Liang, Jonathan Fisher, Umber Cheema

Abstract

The biological behaviour of the cancer cell is in part controlled by its microenvironment and in part by underlying genetics. The interaction of cancer cells with the surrounding stroma directs cancer progression. The most common primary malignant tumour of the bone, osteosarcoma, is a highly complex disease in terms of its progression, invasion, and metastasis. To better understand disease characteristics and develop accurate therapies for osteosarcoma, novel tissue models have been developed to systematically understand how facets of the tumour microenvironment (TME) can influence cancer cell behaviour. This study aims to understand how osteosarcoma invasion and metastasis is influenced by different types of stromal cells in the TME. The engineering of complex tumouroids, which segregate the tumour and stromal cells in specific 3D compartments, allows for the study of tumour-stroma interaction and invasion of cells between different compartments. Complex tumouroids comprised a central osteosarcoma tumour mass with different engineered stromal compartments, representative of the primary bone or metastatic lung. Spatial Transcriptomics (ST) unveiled that osteosarcoma cells upregulated metastatic genes such as IFI27 in the presence of a lung stromal compartment, whereas a bone stromal compartment resulted in the upregulated of oncogenes and drug resistance genes such as DUSP1 and HIF1A within the osteosarcoma compartment. Engineering a primary stromal cell compartment compared to a metastatic stromal cell compartment unveiled how the regulation of cell proliferation, invasion, extracellular matrix (ECM) remodelling, metastasis markers and tumour suppressor markers was altered in the osteosarcoma transcriptome.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Sarcoma Diagnosis and Treatment · Cancer Genomics and Diagnostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (83)

Show source-provided references
1. Identification of key biomarkers and functional pathways in osteosarcomas with lung metastasis: evidence from bioinformatics analysis
2. A 3D collagen-based bioprinted model to study osteosarcoma invasiveness and drug response10.3390/polym14194070 ↗
3. Pulmonary metastasis of osteosarcoma: multiple presentations in a single patient
4. Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma
5. Osteomimetic matrix components alter cell migration and drug response in a 3D tumour-engineered osteosarcoma model10.1016/j.actbio.2019.07.011 ↗
6. Bioengineering the ameloblastoma tumour to study its effect on bone nodule formation10.1038/s41598-021-03484-5 ↗
7. Stromal cells in the tumor microenvironment10.1007/978-3-319-78127-3_6 ↗
8. Modeling physiological events in 2D vs. 3D cell culture10.1152/physiol.00036.2016 ↗
9. In vitro 3D Cultures to Model the Tumor Microenvironment10.3390/cancers13122970 ↗
10. Three-Dimensional Osteosarcoma Models for Advancing Drug Discovery and Development
11. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: a Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research10.1007/978-1-4939-9773-2_25 ↗
12. Multiplex digital spatial profiling of proteins and RNA in fixed tissue10.1038/s41587-020-0472-9 ↗
13. GeoMx™ RNA assay: high multiplex, digital, spatial analysis of RNA in FFPE tissue BT
14. Modelling stromal compartments to recapitulate the ameloblastoma tumour microenvironment10.1016/j.mbplus.2022.100125 ↗
15. Bakkalci D., Al-Badri G., Yang W., Nam A., Liang Y., Khurram S.A., et al. Spatial transcriptome profiling of in vitro 3D tumouroids to study tumour-stroma interactions. bioRxiv. 2022.10.1101/2022.12.13.520130 ↗
16. Best practices for spatial profiling for breast cancer research with the geomx(®) digital spatial profiler10.3390/cancers13174456 ↗
17. sCLU as prognostic biomarker and therapeutic target in osteosarcoma10.1080/21655979.2019.1621136 ↗
18. Role of aldolase A in osteosarcoma progression and metastasis: in vitro and in vivo evidence10.3892/or.2014.3473 ↗
19. PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p10.1186/s13046-022-02339-9 ↗
20. Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients10.3390/ijms21197295 ↗
21. BIRC7 and STC2 Expression are associated with tumorigenesis and poor outcome in extrahepatic cholangiocarcinoma10.1177/1533033820971676 ↗
22. Lipocalin-2 inhibits osteosarcoma cell metastasis by suppressing MET expression via the MEK-ERK pathway10.3390/cancers13133181 ↗
23. Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications10.1134/S0006297918110019 ↗
24. Thrombospondin 1 Triggers Osteosarcoma Cell Metastasis and Tumor Angiogenesis10.3727/096504018X15208993118389 ↗
25. CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule [Internet]10.3389/fcell.2019.00066 ↗
26. IGFBP-3 stimulates human osteosarcoma cell migration by upregulating VCAM-1 expression10.1016/j.lfs.2020.118758 ↗
27. Effects of FOSL1 silencing on osteosarcoma cell proliferation, invasion and migration through the ERK/AP-1 signaling pathway10.1002/jcp.27048 ↗
28. miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma10.3892/or.2012.1995 ↗
29. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway10.1016/j.bbrc.2016.01.090 ↗
30. Hypoxia-inducible factor-1 promotes cancer progression through activating AKT/Cyclin D1 signaling pathway in osteosarcoma10.1016/j.biopha.2018.03.165 ↗
31. Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells10.3892/or.2014.3181 ↗
32. DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer
33. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy10.1007/s13277-010-0146-1 ↗
34. The role of IL-1B in breast cancer bone metastasis10.1530/ERC-17-0309 ↗
35. Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro10.1016/j.biopha.2019.108949 ↗
36. EMR1/ADGRE1 expression in cancer cells upregulated by tumor-associated macrophages is related to poor prognosis in colorectal cancer10.3390/biomedicines10123121 ↗
37. TP53 mutations and survival in osteosarcoma patients: a meta-analysis of published data10.1155/2016/4639575 ↗
38. HSPA6 and its role in cancers and other diseases10.1007/s11033-022-07641-5 ↗
39. Potential diagnostic value of the differential expression of histone H3 variants between low- and high-grade gliomas10.3390/cancers13215261 ↗
40. Downregulation of TAP1 and TAP2 in early stage breast cancer10.1371/journal.pone.0187323 ↗
41. Identification of potential crucial genes and key pathways in osteosarcoma10.1186/s41065-020-00142-0 ↗
42. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma10.3892/or.2020.7686 ↗
43. Inhibition of PLA2G4A reduces the expression of lung cancer-related cytokines10.1089/dna.2018.4286 ↗
44. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade10.1038/s41422-019-0224-x ↗
45. IFI35 promotes renal cancer progression by inhibiting pSTAT1/pSTAT6-dependent autophagy10.3390/cancers14122861 ↗
46. Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma10.1002/cam4.3361 ↗
47. ADAMTS7 degrades Comp to fuel BMP2-dependent osteogenic differentiation and ameliorate oncogenic potential in osteosarcomas10.1002/2211-5463.12939 ↗
48. The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma10.1002/1878-0261.12760 ↗
49. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma10.1038/s41467-020-20059-6 ↗
50. ROCK1 as a potential therapeutic target in osteosarcoma10.1002/jor.21403 ↗
51. Mitogenic action of insulin-like growth factor-I on human osteosarcoma MG-63 cells and rat osteoblasts maintained in situ: the role of glucose-6-phosphate dehydrogenase10.1016/S0169-6009(08)80222-X ↗
52. The role of fibroblast activation protein in progression and development of osteosarcoma cells10.1007/s10238-019-00591-6 ↗
53. NFIL3 acts as a nuclear factor to increase osteosarcoma progression10.1155/2019/4068521 ↗
54. JAK1/STAT3 regulatory effect of β-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation10.1002/jbt.22514 ↗
55. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells10.1002/jcp.27435 ↗
56. IFI6 depletion inhibits esophageal squamous cell carcinoma progression through reactive oxygen species accumulation via mitochondrial dysfunction and endoplasmic reticulum stress10.1186/s13046-020-01646-3 ↗
57. Two HLA Class II gene variants are independently associated with pediatric osteosarcoma risk
58. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma10.1038/s41467-020-14639-9 ↗
59. Mutational drivers of cancer cell migration and invasion10.1038/s41416-020-01149-0 ↗
60. Concepts of extracellular matrix remodelling in tumour progression and metastasis10.1038/s41467-020-18794-x ↗
61. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion
62. COL5A2 inhibits the TGF-β and Wnt/β-catenin signaling pathways to inhibit the invasion and metastasis of osteosarcoma [Internet]
63. mTOR signaling in osteosarcoma: oncogenesis and therapeutic aspects (Review)10.3892/or.2016.4922 ↗
64. The MYC oncogene is a global regulator of the immune response10.1182/blood-2017-11-742577 ↗
65. CDKN2B-AS1 Exerts Oncogenic Role in Osteosarcoma by Promoting Cell Proliferation and Epithelial to Mesenchymal Transition
66. Effectiveness of sulforaphane as a radiosensitizer for murine osteosarcoma cells10.3892/or.2012.2195 ↗
67. Forecast of actin-binding proteins as the oncotarget in osteosarcoma – a review of mechanism, diagnosis and therapy10.2147/OTT.S159894 ↗
68. POLR2A promotes the proliferation of gastric cancer cells by advancing the
69. PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas10.1158/1541-7786.MCR-18-0777 ↗
70. PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-κB/IL8 pathway10.1038/s41420-021-00410-6 ↗
71. JAK1 inactivation promotes proliferation and migration of endometrial cancer cells via upregulating the hypoxia-inducible factor signaling pathway10.1186/s12964-022-00990-5 ↗
72. Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma10.1038/s41416-020-0973-9 ↗
73. Cancer invasion regulates vascular complexity in a three-dimensional biomimetic model10.1016/j.ejca.2019.07.005 ↗
74. In vitro three-dimensional organotypic culture models of the oral mucosa10.1007/s11626-020-00539-1 ↗
75. Development of an In vitro 3D Model for Investigating Ligamentum Flavum Hypertrophy10.1186/s12575-020-00132-6 ↗
76. RhoA enhances osteosarcoma resistance to MPPa-PDT via the Hippo/YAP signaling pathway10.1186/s13578-021-00690-6 ↗
77. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha10.1371/journal.pone.0065304 ↗
78. Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma10.1177/15353702221088238 ↗
79. Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma10.1177/1758835920922055 ↗
80. Bhat R. Matrix adhesion and remodeling diversifies modes of cancer invasion across spatial scales10.1016/j.jtbi.2021.110733 ↗
81. Matrix Metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances10.3390/s18103249 ↗
82. Thrombospondin-1 promotes cell migration, invasion and lung metastasis of osteosarcoma through FAK dependent pathway10.18632/oncotarget.17427 ↗
83. Targeting the VEGF pathway in osteosarcoma10.3390/cells10051240 ↗